Covid-19 detection concept is undoubtedly one of the strongest main lines in the recent A-share market. Affected by the spread of Omicron mutant strain, covid-19 detection related stocks were sought after with funds, and the stock price set off a wave of limit one after another.
Among them, the performance of anxiu biology, a new share of Kechuang board, is more prominent. Since landing on the science and innovation board in November last year, the share price of Asahi biology has continued to rise. Since the new year, it has gained several “20cm” trading limits, with a cumulative increase of nearly 300% in the past two months.
In the process of the sharp rise of an Xu biology, an in-depth research report issued by Shanghai Securities Research Institute attracted attention.
In the report, Shanghai Securities predicts that an Xu biology will realize a net profit attributable to its parent company of 2.988 billion yuan in 2022, a significant increase of 311.5% over the predicted value in 2021; It is estimated that the reasonable market value of the company is about 25.2 billion yuan, which has nearly 60% growth space compared with the date of the research report.
Although the prospect described in this research report is very wonderful, it has ushered in an embarrassing response from listed companies.
An Xu biology then disclosed the announcement for clarification, expressing concern that Shanghai Securities Research Institute has made a profit forecast on the company’s performance from 2022 to 2023 through the research report, and explained to the company: the company has not received any form of interview and research and other activities from relevant personnel of Shanghai Securities; The report is only the opinions of Shanghai Securities Research Institute and does not represent the position of the company.
why does the brokerage Research Report sing more profit prospects
On January 11, Shanghai Securities Research Institute released the Research Report of individual stocks of Asahi biology, entitled “in depth report of Asahi biology: independent and controllable raw materials, leading the development of POCT detection”, which is 40 pages long.
On January 11, Shanghai Securities Research Institute released an Xu biological in-depth research report
Shanghai Securities said in the report that it continues to be optimistic about the POCT detection track with a broad market. Asahi bio is a core POCT reagent provider with high self supply capacity of raw materials and rich categories in the high-quality track. Driven by the overseas epidemic catalysis and the sales of exclusive self-test pens, its performance is expected to increase significantly. In the future, the company can also carry out product R & D, channel expansion and capacity improvement with the help of a large amount of profitable cash, which has a broad prospect.
In the “investment proposal”, Shanghai securities issued the recommended “buy” rating, and it is expected that Asahi biology will realize net profit attributable to parent company of RMB 726 million, RMB 2.988 billion and RMB 1.655 billion from 2021 to 2023, with a year-on-year increase of 11.9% / 311.5% / – 44.6%, corresponding to PE valuation of 15.08 times / 3.67 times / 6.62 times (calculated based on the closing price on January 7).
From Shanghai Securities Research Report
Shanghai Securities also adopts the segment valuation method, and it is estimated that the “reasonable market value” of the company is about 25.2 billion yuan. As of the close of the research report, the total market value of Asahi biology was 15.775 billion yuan, with 60% potential growth space compared with the two.
the listed company said:
never received institutional research after listing
Looking back, the release time of this research report of Shanghai Securities is in the period when the share price of Anxi biology rises most sharply. On the day of the release of the Research Report on January 11, the share price of Asahi biology increased by 20%, which was the fourth consecutive day.
It is noteworthy that for the Research Report of Shanghai Securities, an Xu biology then responded through an announcement.
An Xu biology recently disclosed the announcement on pre increase and clarification of annual performance in 2021, saying that the company is concerned that the research report published by Shanghai Securities Research Institute has made a profit forecast on the company’s performance from 2022 to 2023. In order to avoid misleading investors and safeguard the legitimate rights and interests of the company, the company hereby makes the following explanations:
1. The company has not accepted any form of interview and research and other activities by relevant personnel of Shanghai Securities, nor has it provided undisclosed relevant performance data and company operation data to the outside world.
2. The report is only the opinions of Shanghai Securities Research Institute and does not represent the position of the company. Up to now, the company has not made any performance forecast from 2022 to 2023. In view of the overseas epidemic development and control, the selection of detection methods, overseas market promotion, customer recognition, market competition, epidemic prevention and control policies of other countries and other influencing factors, the company cannot predict the performance from 2022 to 2023.
An Xu biology issued “clarification on Securities Research Report”
An Xu biology also said: after the company’s listing, it has never accepted any form of interview and research and other activities from any investment institution, nor has it provided relevant performance data and company operation data that have not been disclosed to the outside world.
From this point of view, this in-depth research report released by Shanghai Securities Research Institute seems to be suspected of “making cars behind closed doors”.
Research Report on “face beating” securities companies of the company
In recent years, the events of listed companies personally “beating the face” in the Research Report of securities companies have occurred repeatedly. It is by no means the first time to question the “behind closed doors” of securities analysts. The most classic example is National Silicon Industry Group Co.Ltd(688126) in 2020.
In April 2020, National Silicon Industry Group Co.Ltd(688126) landed on the science and innovation board and became a star stock in the market after listing. The share price soared nearly 600% in less than three months.
During the National Silicon Industry Group Co.Ltd(688126) stock price surge, many brokerage research institutes “sing more in fancy”, and the profit forecast and target price given to the company are very bold.
However, after the stock price soared for a short time, National Silicon Industry Group Co.Ltd(688126) disclosed an announcement that instantly “slapped” many analysts.
National Silicon Industry Group Co.Ltd(688126) said that the company is concerned about the prediction of the company’s future performance, earnings per share, stock price, market value and other indicators in the research reports issued by some securities companies. Now the risk tips are as follows:
Since its listing, the company has not accepted the investigation of investment institutions and securities companies. Some research reports have great differences between the company’s performance prediction and the company’s historical performance, and the basis for the company’s stock price prediction is insufficient. It is its unilateral prediction, which has not been confirmed by the company, and the relevant information shall be subject to the company’s announcement.
In the past two years, looking back at the profit forecast issued by securities companies to National Silicon Industry Group Co.Ltd(688126) at that time, there are indeed many deviations. With the ebb of capital sentiment, National Silicon Industry Group Co.Ltd(688126) share price also fell from the high point two years ago, and has retreated more than 60% from the high point.
